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2
Recent Work has demonstrated that complement compo

COMPOSITIONS AND METHODS FOR
INHIBITING DRUSEN COMPLEMENT
COMPONENTS C3A AND C5A FOR THE
TREATMENT OF AGE-RELATED MACULAR
DEGENERATION

nents C3 and C5 are principal constituents of drusen in

patients With AMD. Mullins, R. F., Russell, S. R., Anderson,
D. H. & Hageman, G. S. (2000) FASEB J 14, 835-46;
Johnson, L. V., OZaki, S., Staples, M. K., Erickson, P. A. &

Anderson, D. H. (2000) Exp Eye Res 70, 441 -9; Anderson, D.
H., Mullins, R. F., Hageman, G. S. & Johnson, L. V. (2002)
Am J Ophthalmol 134, 411-31; and Leitner, W. P., Staples, M.
K. & Anderson, D. H. (2001) Exp Eye Res 73, 887-96. Their

This application is a continuation-in-part to US. patent
application Ser. No. 10/685,705 ?led Oct. 16, 2003 now US.
Pat. No. 7,595,430 Which claims priority to US. provisional

application Ser. No. 60/422,096, ?led Oct. 30, 2002, each of
Which are incorporated herein in their entirety.

presence as Well as that of the membrane-attack-complex

(MAC) C5b-9 and other acute phase reactant proteins in RPE
cells overlying drusen has fueled speculation that drusen bio
genesis involves chronic in?ammatory processes that either
can trigger complement activation and formation of MAC
acting to lyse RPE cells or disturb physiological homeostasis
in RPE cells. Johnson, L. V., et al. (2001) Exp Eye Res 73,

GOVERNMENT SUPPORT

This invention Was made With government support under

grant numbers: (1) NIH EY015422 aWarded by the National
Eye Institute of the National Institutes of Health (NEI/NIH),

887-96.
Recently We described an animal model of AMD in aged

(2) 5T32DC000065 (training grant) aWarded by the National
Institute on Deafness and Other Communication Disorders of

the National Institutes of Health (NIDCD/NIH), (3) NIH
GM62134 aWarded by the NIH, and (4) NIH GM069736
aWarded by the NIH. The government has certain rights in the

20

A., Rollins, B. J. & Ambati, B. K. (2003) Nat Med 9, 1390
1397. Interestingly, RPE and choroidal deposits of C3 and C5
25

This invention relates to compositions and methods for

treating and/or preventing age-related macular degeneration
(AMD). More particularly, the invention relates to the use of
antagonists and antibodies to activated complement compo
nent 3 (C3a) and/or its receptor (C3aR), and activated

30

are more than mere mediators of innate immunity. To date,
35

their in?uence on the molecular regulation of angiogenesis in
vivo has not been addressed. Because drusen predispose to

and predate CNV, We explored Whether C3a and C5a (the
activated forms) play a role in CNV development by studying
their impact on VEGF expression, and also in laser-induced
CNV, an accelerated model of neovascular AMD that repro

BACKGROUND OF THE INVENTION
40

duces much of the pathology and immunophenotype of
human CNV (RevieWed in Ambati, J ., et al. (2003) Surv

Age-related macular degeneration (AMD) is the leading

Ophthalmol 48, 257-293), using mice de?cient in receptors

cause of permanent vision loss among the elderly in many

industrialized countries. Smith, W., Assink, J., Klein, R.,
Mitchell, P., Klayer, C. C., Klein, B. E., Hofman, A., Jensen,
S., Wang, J. J. & de Jong, P. T. (2001) Ophthalmology 108,

also are found in these mice at a young age. The inability of

these mice, Which are impaired in induced macrophage traf
?cking, to clear these complement deposits is thought to
promote the later development of CNV via upregulation of
RPE cell secretion of VEGF. Id. These ?ndings suggest a
mechanistic link betWeen deposition of complement compo
nents in drusen and the development of CNV.

There is groWing evidence that complement components

complement components 5 (C5a) and/or its receptor (C5aR)
to reduce vascular endothelial groWth factor (VEGF) expres
sion and inhibit choroidal neovasculariZation (CNV). This
invention also relates to an assay for the detection of C3a,
C3aR, C5a and/or C5aR as a predisposition for and/or early
detection of AMD.

logical features seen in the human condition. Ambati, J .,

Anand,A., FemandeZ, S., Sakurai, E., Lynn, B. C., KuZiel, W.

invention.
FIELD OF THE INVENTION

Ccl2_/_ and Ccr2_/_ mice, Which develop many salient patho

for C3a or C5a. The effect of modulating C3a and C5a reveals
45

novel therapeutic strategies to modulate angiogenesis in the
setting of in?ammation and highlights the importance of
developing the ability to assay expression of markers such as
C3a and C5a to for diagnostics and to target therapeutics more

697-704. The majority ofvision loss due to AMD is a result of

pathologic neW blood vessels, termed CNV, invading the
retina from the underlying choroid through fractures in Bruch

speci?cally.

membrane, the extracellular matrix betWeen the choroid and

the retinal pigment epithelium (RPE). The earliest clinical

50

SUMMARY OF THE INVENTION

hallmark of AMD is the appearance of drusen (Gass, J. D.

(1972) TransAm Ophthalmol Soc 70, 409-36), localiZed lipo

In one aspect of the invention there is provided composi

proteinaceous deposits betWeen the RPE and Bruch mem
brane. Although their presence is an epidemiological risk

factor for the development of CNV (Bressler, S. B., Maguire,
M. G., Bressler, N. M. & Fine, S. L. (1990)Arch Ophthalmol

tions for treating and/ or preventing AMD. In one embodiment

there are ophthalmic compositions for treating and/or pre
55

venting CNV comprising one or more of, an inactivating

agent that binds selectively to C3a and/ or its receptor (C3aR),

108, 1442-7; and Macular Photocoagulation Study Group
(1997) Arch Ophthalmol 115, 741-7), the mechanism ofhoW,

an inactivating agent to C5a and/or its receptor (C5aR), or a

or if, drusen provoke CNV remains unde?ned. Some inves
ti gators have suggested that drusen are epiphenomena, While

more inactivating agent is an antagonist to C3a, C3aR, C5a,

combination thereof. In a preferred embodiment the one or
60

others have claimed that drusen constituents act as a focal

another preferred embodiment, the compositions further

stimulus for in?ammatory cells that secrete angiogenic mol
ecules such as VEGF, and still others have suggested that

comprise one or more pharmaceutical agent operatively
attached to the inactivating agent. In another aspect of the

drusen disturb RPE homeostasis by impairing transport
across Bruch membrane. RevieWed in Ambati, J ., Ambati, B.

K., Yoo, S. H., Ianchulev, S. & Adamis, A. P. (2003) Surv

Ophthalmol 48, 257-293.

C5aR, or a combination thereof. In another preferred embodi
ment, the one or more inactivating agent is an antibody. In still

65

invention there is provided methods of using the composi
tions described herein to inhibit VEGF expression; to inhibit
CNV; to prevent and/or treat AMD.

US 7,816,497 B2
4

3

tissue Within laser scars in Wild-type (A), C3aR_/_ (B) and

In another aspect of the invention there is provided meth

C5aR_/_ (C) mice demonstrate more than 40% reduction in

ods for treating and/ or preventing AMD. In one embodiment
there are methods for treating and/ or preventing CNV com

CNV volume (D). *P<0.05 compared to Wild-type (Wt) mice.

prising administering to the eye of a subject a therapeutically

Scale bar 100 um.

FIG. 6 (A-B). (A) CNV is reduced in Wild-type mice

effective amount of a composition comprising one or more of,

an inactivating agent that binds selectively to C3a, C3aR,

treated With C3aRA or C5aRA compared With control pep

C5a, C5aR, or a combination thereof. In a preferred embodi
ment the one or more inactivating agent is an antagonist to

tide, only if inj ected immediately after laser injury. (B) CNV
is reduced in Wild-type mice treated With neutralizing anti
C3a or anti-C5a antibodies compared With isotype control

C3a, C3aR, C5a, C5aR or a combination thereof. In another
preferred embodiment, the one or more inactivating agent is

antibodies, only if injected immediately after laser injury.

an antibody. Preferably, administration of such one or more

DETAILED DESCRIPTION OF THE INVENTION

antagonist or antibody to C3a, C3aR, C5a or C5aR reduces

VEGF expression. In still another preferred method, the inac
tivating agent is operatively attached to one or more pharma

All publications, patents and patent applications cited

ceutical agent, having therapeutic or toxic effects.
In another aspect of the invention there is provided meth
ods, assays and kits for detecting the presence of C3a, C3aR,

herein, Whether supra or infra, are hereby incorporated by
reference in their entirety.

C5a and/or C5aR for diagnostic and treatment purposes. In a
preferred embodiment, one or more of, an antibody to C3a,
C3aR, C5a, C5aR, or a combination of both is introduced to
the eye or to a sample from the eye of a patient and the

presence of C3a, C3aR, C5a and/or C5aR is detected. Pref
erably, antibody is labeled With a detectable label. Examples
of such detectable labels include those that are, for example,
radioactive, ?uorescent, chemiluminescent or absorbant
based, or a combination of the foregoing. The presence of
C3a, C3ar, C5a, C5aR or a combination thereof is detected by
determining Whether an antibody binds selectively to a com
ponent of the eye. Detection or increased level of C3a, C3aR,
C5a and/or C5aR in comparison to levels of a sample from a
normal subject is indicative of a predisposition for or neovas

As used herein, the term “antagonist” means any molecule
that binds to certain proteins (e.g., receptors, enzymes) at a
speci?c (active) site on that protein, Which binding sup
20

mean any interaction, Whether via direct or indirect means,

Whichbinds, combines, couples, links, or unites molecules by
25

example, a speci?ed protein, receptor or protein/receptor sub
30

As used herein, the term “binds selectively to” means that

binds to one or more of C3a, C3aR, C5a, or C5aR.
35

FIG. 1 (A-B). C3a and C5a upregulate VEGF in vitro and

in vivo. Human C3a (50 ng/ml) and C5a (50 ng/ml) upregu
lated human RPE cell secretion of VEGF (A). Intravitreous
injection of human C3a or C5a increase VEGF levels in the
40

45

surface of RPE cells in the area of injury (B,E) and next to the

PRrphotoreceptor nuclei, Scl:sclera. Scale bar 20 um.
FIG. 3 (A-B). Laser-induced VEGF induction is dimin
ished in C3aR_/_ and C5aR_/_ mice. VEGF levels in the
RPE/choroid, Which peak 3 day after laser injury (A) are
signi?cantly reduced in both knockout strains (B). *P<0.05

50

55

confocal images (1 pm sections) of FITC-isolectin B4 labeled

and/or C5aR for Which the antibodies or compounds are

speci?c.
As used herein, the term “expression” means the detectable
effect of a gene, like a nucleic acid sequence encoding VEGF.
The term “express” means to manifest the detectable effect of
a gene. A gene may be expressed inside a cell, on the surface
of a cell or be secreted by the cell.
As used herein, the term “inactivate” refers to the act of
C3aR, C5a and/or C5aR function to induce VEGF expres
sion.

As used herein the term “inactivating agent” encompasses

small molecules, compounds or antibodies that modulate,
bind to, and/ or inactivate C3a, C3aR, C5a and/or C5a, and/ or
60

prevent C3a, C3aR, C5a and/or C5aR from inducing VEGF
expression. Preferably, toxic side-effects are minimized. By
“inactivating” it is meant that the agent may functionally
inhibit, prevent, neutralize or suppress, C3a, C3aR, C5a and/
or C5aR activity (function) that leads to VEGF expression.

65

As used herein, the term “introducing” means any means of
delivery or administration, Whether in vivo or in vitro, includ

both knockout strains (D). *P<0.05 compared to number of
FIG. 5 (A-D). CNV is reduced in knockout mice. Stacked

Which alloWs the component to Which they are operatively
attached to be detected, and further quanti?ed if desired.
As used herein, the term “diagnostically effective” means
that the amount of detectably labeled compound, such as
monoclonal antibody or other compound, is administered in
suf?cient quantity to enable detection of C3a, C3aR, C5a

a group of functionally or structurally related proteins or

(B). Macrophage in?ltration (normalized to peak), Which
peaks 3 days after laser injury (C) is signi?cantly reduced in
cells before injury (A,C) and to Wild-type (Wt) mice (B,D).

As used herein, the term “detectable label(s)” are com
pounds or elements that can be detected due to their speci?c
functional properties, or chemical characteristics, the use of

inhibiting, preventing, suppressing or neutralizing C3a,

compared to level before injury (A) and to Wild-type (Wt)
mice (B).
FIG. 4 (A-D). Leukocyte recruitment to the choroid is
diminished in C3aR_/_ and C5aR_/_ mice. Neutrophil in?l
tration (normalized to peak), Which peaks 1 day after laser
injury (A) is signi?cantly reduced in both knockout strains

unit, antibody-antigen interaction, covalent binding, and any
non-covalent binding including disul?de bonds, Vander
Waals, electrostatic force, and hydrostatic force.

the inactivating agent, including antagonists, antibodies,
compounds, compositions, formulation, nucleic acids, etc.,

BRIEF DESCRIPTION OF THE DRAWINGS

area of injury (C,F) 12 hours after injury, but not in uninjured
areas (D,G). ArroWs shoW RPE cell nuclei. Ch:choroid,

means of reactive groups, either in the molecules per se or in

a chemical added for that purpose, as in the affects of, for

cular disease, like AMD.

RPE/choroid (solid lines) but not in the neurosensory retina
(dotted lines) in a dose-dependent fashion 4 hours after inj ec
tion (B). *P<0.05 compared to PBS (A) and to 0 ng (B).
FIG. 2 (A-G). Laser injury induces C3 and C5 deposition.
Western blotting shoWs increasing levels of C3 and C5 in the
RPE/choroid of Wild-type mice Within 6 hours of injury and is
sustained for at least 24 hours (A). C5 (B,C,D) and C3 (E,F,G)
are deposited (red) in the RPE cell layer and on the apical

presses, inhibits, impedes or neutralizes the activity (func
tion) or effect of the protein.
As used herein, the terms “bind”, “binding” or “bound”

ing simple contact.

US 7,816,497 B2
6
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As used herein, the term “neovascular disease” refers to

Anand, A., Ambati, B. K., van Rooijen, N. & Ambati, 1.

age-related macular degeneration (AMD), including Wet
AMD (classic, occult, subfoveal, extrafoveal, juxtafoveal)

(2003) Invest Ophthalmol V1.3‘ Sci 44, 3578-85), suggesting
that resident cells such as CBC and RPE cells are responsible.
There Was no increase in the number of macrophages or

and dry AMD, cancer, choroidal neovasculariZation, corneal
neovasculariZation, cystoid macular edema, diabetic retin
opathy, diabetic macular edema (DME), in?ammatory or
mechanical macular degeneration, iris neovasculariZation,
myopic macular degeneration, macular degeneration due to

neutrophils in the choroid 4 hours after intravitreous injection
of C3a or C5a, indicating that the increase in VEGF expres
sion Was due to resident cells (data not shoWn). C3 and C5
expression Was detected by Western blotting in the RPE/
choroid Within 6 hours of injury, Which persisted for at least

histoplasmosis or angioid streaks or inherited retinal or cho

roidal dystrophies/degenerations, proliferative diabetic retin
opathy, psoriasis, retinal neovasculariZation, vitreal neovas
culariZation, branch/central retinal vein occlusion,
retinopathy of prematurity, rheumatoid arthritis, uveitis, or

24 hours (FIG. 2A). Immunostaining revealed signi?cant
amounts of C3 and C5 deposition in and near RPE cells in the

area of injury (FIGS. 2B,E). RPE cells adjacent to the site of
injury also stained for C3 and C5, While uninjured areas
exhibited minimal if any staining for these complement com

infection.
As used herein, the term “neovasculariZation” means pro

ponents (FIGS. 2C,D,F,G). The absence of an effect of C3a or
C5a on CBC in vitro corresponded With the negligible stain

liferation of blood vessels in tissue not normally containing
them, or proliferation of blood vessels of a different kind than
usual in tissue. Non-limiting examples of ocular neovascu
lariZation include neovasculariZation of the choroid (includ

ing, classic, occult, Type 1, and Type 2 choroidal), cornea,
iris, retina, retinal pigmented epithelium (RPE), and/ or vitre

20

The inventor has found that there is no signi?cant increase
in VEGF levels at any time point in C3aR_/_ and C5aR_/_
mice folloWing injury. VEGF levels in the RPE/choroid one

ous. Ocular neovasculariZation is also associated With eye

neovascular disease such as, for example, AMD, choroidal

neovasculariZation, cystoid macular edema, DME, diabetic

retinopathy, in?ammatory diabetic retinopathy, retinopathy

25

day after injury Were signi?cantly reduced in C3aR_/_

30

P:0.04) compared to Wild-type mice. The lack of an initial
rise in VEGF immediately after injury in these animals is
attributed to the disruption of C3a and C5a induced VEGF.
Reduced VEGF levels persisted even 3 days after injury

of prematurity, and traumatic eye injury.

(48.6%:7.5%; P:0.06) and C5aR_/_ mice (55.4%:3.1%;

As used herein, the term “operatively attached” means

association With, or attachment, conjugation, linking, orbind
ing (direct or indirect by use of another molecule, linker, etc.)
of one molecule, including compounds, labels and ligands,

(FIG. 3A), the time point of the peak of the VEGF response
(Sakurai, E., Anand, A., Ambati, B. K., van Rooijen, N. &
Ambati, 1. (2003) Invest Ophthalmol 171s Sci 44, 3578-85), in

amino acid sequence, or nucleic acid sequence, to another
molecule in such a Way as to alloW each of the molecules to
function in their intended manners.

As used herein, the term “patient” includes members of the
animal kingdom including but not limited to human beings.
The inventor has discovered that signi?cant quantities of
complement components C3 and C5 are present Within the

ing of C3 or C5 in the choroid folloWing laser injury. The peak
of the VEGF response 3 days after injury parallels the in?l
tration of macrophages and can be blunted by macrophage
depletion, suggesting that it is these recruited cells that are
responsible for the second surge in VEGF.

35

C3aR'/' (60.9%:4.9%; P:0.01) and C5aR'/' mice
(62.5%:3.1%; P:0.004) compared to Wild-type mice (FIG.
3B). The peaks of VEGF in C3aR_/_ and C5aR_/_ mice fol
loWing laser injury Were not elevated above pre-injury levels

RPE/choroid soon after laser injury, and that laser-induced

in Wild-type mice (P:0.99). The missing secondary surge in

CNV is signi?cantly reduced in C3aR_/_ and C5aR_/_ mice
via concerted suppression of leukocyte recruitment and
VEGF expression. The inventor has also demonstrated that
C3a and C5a upregulate RPE/choroid production of VEGF in

VEGF in C3aR_/_ and C5aR_/_ mice might be due both to the
40

induced CNV (Sakurai, E., Taguchi, H., Anand, A., Ambati,
B. K., Gragoudas, E. S., Miller, 1. W.,Adamis,A. P. &Ambati,

the uninjured eye in a dose-dependent manner, consistent
With their ability to upregulate RPE cell secretion ofVEGF in

vitro, and that VEGF upregulation induced by laser injury is
abrogated in C3aR_/_ and C5aR_/_ mice.

45

In disease states such as AMD Where the integrity of the
RPE cell monolayer is compromised in some but not all
regions, RPE cells Would be expected to exist both con?uent

(quiescent) and subcon?uent (proliferating) conditions. In

50

Which occurred 3 days after injury (FIG. 4C), Was reduced in
55

KuZiel, W. A., Rollins, B. 1., Ambati, B. K. (2003) NatMed 9,
1390-1397. This response Was preserved in vivo as intravit
60

absence of a similar effect in the neurosensory retina demon
strated that VEGF upregulation Was not a non-speci?c

response to intraocular injection.
In the laser injury model, the initial rise in VEGF levels

occurred prior to the in?ltration of leukocytes (Sakurai, E.,

C3aR'/' (49.1%:4.6%; P:0.04) and C5aR'/' mice (42.1%+
2.1%; P:0.05) compared to Wild-type mice (FIG. 4D). This
may be due to direct interception of the chemotactic function
of C3aR and C5aR on leukocytes or reduction in VEGF,
Which itself is a chemoattractant. Barleon, B., SoZZani, S.,

Ambati, 1., Anand,A., Fernandez, S., Sakurai, E., Lynn, B. C.,
reous injection of C3a or C5a in Wild-type mice upregulated
VEGF expression in the RPE/choroid in a dose-dependent
fashion Within 4 hours of administration (FIG. 1B). The

1. (2003) Invest Ophthalmol 171s Sci 44, 2743-9; and Sakurai,
E., Anand, A., Ambati, B. K., van Rooijen, N. & Ambati, 1.
(2003) Invest Ophthalmol 171s Sci 44, 3578-85), Was also
markedly reduced in C3aR_/_ and C5aR_/_ mice folloWing
injury. The peak of neutrophil in?ltration into the choroid,
Which occurred 1 day after injury (FIG. 4A), Was reduced in

C3aR'/' (57.8%:9.0%; P:0.05) and C5aR'/' mice
(66.6%:1.7%; P:0.02) compared to Wild-type mice (FIG.
4B). The peak of macrophage in?ltration into the choroid,

both conditions the inventor discovered that C3a and C5a
induced VEGF in RPE cells. Both C3a and C5a upregulated

the secretion ofVEGF by human RPE cells, both in con?uent
and subcon?uent conditions (FIG. 1A), but not in human
choroidal endothelial cells (CEC; data not shoWn) in vitro,
con?rming a previous observation about the effect of C5a.

interference With complement component receptor mediated
signaling and also the reduction in leukocyte recruitment.
Leukocyte recruitment, Which plays a pivotal role in laser
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Zhou, D., Weich, H. A., Mantovani, A. & Mar'me, D. (1996)
Blood 87, 3336-43; and Clauss, M., Weich, H., Breier, G.,
Knies, U., Rockl, W., Waltenberger, 1. & Risau, W. (1996) J
Biol Chem 271, 17629-34. It also may result from indirect
reduction of chemokines such as Ccl-2 and Cxcl-2, Which the
inventor and others have shoWn can be induced by comple

ment components. Ambati, 1., Anand, A., FemandeZ, S.,
Sakurai, E., Lynn, B. C., KuZiel, W. A., Rollins, B. 1. &
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Ambati, B. K. (2003) Nat Med 9, 1390-1397; Fukuoka, Y.,
Strainic, M. & Medof, M. E. (2003) Clin Exp Immunol 131,
248-53; CZermak, B. J., Sarma, V., Bless, N. M., Schmal, H.,
Friedl, H. P. &Ward, PA. (1999) Jlmmunol 162, 2321-5; and
Laudes, I. J., Chu, J. C., Huber-Lang, M., Guo, R. F., Riede
mann, N. C., Sarma, J. V., Mahdi, E, Murphy, H. S., Speyer,
C., Lu, K. T., Lambris, J. D., Zetoune, F. S. & Ward, P. A.
(2002) Jlmmunol 169, 5962-70.
While RPE cells constitutively produce both Ccl-2 (Elner,
V. M., Bumstine, M.A., Strieter, R. M., Kunkel, S. L. & Elner,
S. G. (1 997) Exp EyeRes 65, 781-9; and Holtkamp, G. M., De
Vos, A. F., Peek, R. & Kijlsta, A. (1999) Clin Exp Immunol
118, 35-40) andVEGF (Adamis, A. P., Shima, D. T.,Yeo, K.
T., Yeo, T. K., BroWn, L. F., Berse, B., D’Amore, P. A. &
Folkman, J. (1993) Biochem Biophys Res Commun 193, 631
8), the stimuli inducing their overexpression in human CNV
(Grossniklaus, H. E., Ling, J. X., Wallace, T. M., Dithmar, S.,
LaWson, D. H., Cohen, C., Elner, V. M., Elner, S. G. &
Stemberg, P., Jr. (2002) Mol [6s 8, 119-26; Frank, R. N.,
Amin, R. H., Eliott, D., Puklin, J. E. &Abrams, G. W. (1996)
Am J Ophthalmol 122, 393-403; and Lopez, P. F., Sippy, B.
D., Lambert, H. M., Thach, A. B. & Hinton, D. R. (1996)

embodiment there is ophthalmic compositions to treat and/or

prevent choroidal neovasculariZation by reducing VEGF. The
compositions comprise one or more of, an inactivating agent
that binds selectively to C3a, C3aR, C5a, C5aR, or a combi
nation thereof.

The inactivating agent may be an antagonist, antibody,

anti-sense oligonucleotide, aptamer, miRNA, riboZyme,
siRNA, or small molecule. In a preferred embodiment of this

aspect of this invention, the inactivating agent is an antagonist
to C3a, C3aR, C5a and/or C5aR. Non-limiting examples of an
antagonist of the invention include the C3aR antagonist

(C3aRA) N2-[(2,2-diphenylethoxy)acetyl]-1-arginine, the
C3a and C3aR antagonists disclosed in US. Pat. Nos. 5,942,

405 and 6,489,339, the C5aR antagonist (C5aRA) AcF-[OP
dChaWR], and the C5aR antagonists disclosed in US. Pat.

Nos. 6,916,830, 6,884,815, 6,858,637, 6,821,950, 6,777,422,
6,723,743, 6,355,255, 6,270,775, 5,846,547, 5,837,499,
5,807,824, 4,772,584, 4,692,511, or similar peptidases or a

combination thereof. Methods to identify other antagonists
20

are described in US. Pat. Nos. 5,861,272 and 5,614,370.
Other antagonists to C3a, C3aR, C5a and/or C5a knoWn to the
skilled artisan or hereafter discovered may be used. Candi

Invest Ophthalmol J/Is Sci 37, 855-68) are unknown. The

date antagonists include pharmaceutical compounds, small

demonstration that C3a and C5a can trigger Ccl-2 and VEGF
production make them attractive candidates as markers and

molecules, peptides, nucleic acids, including oligonucle
25

otides and polynucleotides in sense or antisense orientation

30

and aptamers.
In another preferred embodiment of this aspect of the
invention, the inactivating agent is an antibody or functional
antibody fragment (Fab) to C3a, C3aR, C5a and/or C5a.
Preferably, the agent is an antagonist to C3a, C3aR, C5a
and/or C5aR. It is also preferable that the agent is an antibody
to C3a, C3aR, C5a and/or C5aR. Non-limiting examples of
antibodies of the invention, include MAb anti-C3a from
Quidel, San Diego, Calif. [catalog no. A203,]; anti-human

35

C3aR antibodies hC3aRZ1 and hC3aRZ2, as described in

modulators of CNV given their presence in drusen deposits in
patients WithAMD and in a mouse model ofAMD, as Well as

folloWing laser injury, particularly because they can be
locally synthesiZed in the RPE. Mullins, R. F., et al. (2000)
FASEB J 14, 835-46; and Johnson, L. V., et al. (2000) Exp Eye
Res 70, 441-9.

By intercepting speci?c receptor-mediated pathways, the
inventor has identi?ed a novel mechanistic association

betWeen the complement and cytokine netWorks in promot
ing laser-induced CNV. These ?ndings introduce the C3a and
C5a complement factors as modulators of angiogenesis in the
eye. These ?ndings also translate into functional inhibition.
The volume of laser-induced CNV Was signi?cantly

reduced in C3aR_/_ (41.5%:5.2%; n:13; P<0.001) and
C5aR_/_ mice (40.8%:4.3%; n:14; P<0.001) compared to
Wild-type mice (n:17) (FIG. 5). To complement the genetic
ablation studies, the inventor tested neutraliZing antibodies
against C3a or C5a and peptide antagonists of their receptors
in Wild-type mice. CNV Was signi?cantly reduced by treat
ment With both peptide antagonists and both neutraliZing
antibodies, compared to control peptide or antibodies, if these
blockers Were injected immediately after laser injury but not
if they Were injected 3 days later (FIG. 6). These data indicate
that the bulk of the pro-angiogenic effects of C3a and C5a in
this model can be attributed to the very early release and

40

anti-EXl human C5aR MAb S5/ 1, as described in Oppera

mann, M., et al., J. Immunol. (1993) October 1; 151(7):3785
45

94; and anti-C5aR MAb S5/1, as described in Kacani, L. et
al., J. Immunol. (2001) 166:3410-3415. Anti-C3 and anti-C5
antibodies may also function to inhibit C3a and/or C3aR or

C5a and/or C5aR, respectively, such as, for example, goat

polyclonal anti-human C5 antibody from Quidel, San Diego,
Calif. [catalog no.A306].Ahybridoma that produces amono
50

clonal anti-C3a, anti-C3aR, anti-C5a and/or anti-C5a anti

55

body that binds to substantially the same epitope as any of the
foregoing antibodies is another aspect of the invention. The
antibodies may be polyclonal antibodies or monoclonal anti
bodies.
Polyclonal antibodies to C3a, C3aR, C5a and C5a can be

deposition of these activated complement components. Sup
pression of CNV in C3aR_/_ and C5aR_/_ mice, and in Wild
type mice treated With antagonists of the activated comple
ment components or their receptors also may be due to

doWnregulation of leukocyte-endothelial adhesion mol

Kacani, L. et al., J. Immunol. (2001) 166:3410-3415; mouse
anti-human C5a antibodies from Hycult Biotechnology BV
of the Netherlands [clones 557, 2942 and 2952]; anti-human
C5a antibody from Tanox, Inc. [137-26], as described in
Fung, M. et al. Clin Exp Immunol. (2003) August; 133(2):
160-9; C5a antibodies disclosed in US. Pat. No. 5,480,974;

A., Chinnaiyan, A. M., Varambally, S., Kumar-Sinha, C.,

produced by various procedures Well knoWn in the art. For
example, puri?ed C3aR, preferably human C3aR, can be

Barrette, T. R., Sarma, J. V. & Ward, P. A. (2004) Am J Pathol
164, 849-859; Ross, G. D., Cain, J. A. & Lachmann, P. J.

administered to various host animals including, but not lim
ited to, rabbits, mice, rats, etc. to induce the production of sera

ecules, Which can be promoted by C3a and C5a (Albrecht, E.

(1985) J Immunol 134, 3307-15; and Lo, S., Detmers, P.,
Levin, S. & Wright, S. (1989) J Exp. Med. 169, 1779-1793)
and are critical for CNV formation. Sakurai, E., et al., (2003)
Invest Ophthalmol VJS Sci 44, 2743-9.
Compositions of the Invention
In one aspect of the invention there is provided composi

60

containing polyclonal antibodies speci?c for the antigen.
Various adjuvants may be used to increase the immunological
response, depending on the host species, and include but are

not limited to, Freund’s (complete and incomplete), mineral
gels such as aluminum hydroxide, surface active substances
65

such as lysolecithin, pluronic polyols, polyanions, peptides,

tions comprising C3a, C3aR, C5a, and/or C5aR inactivating

oil emulsions, keyhole limpet hemocyanins, dinitrophenol,

agents for treating and/or preventing AMD. In a preferred

and potentially useful human adjuvants such as BCG (bacille

US 7,816,497 B2
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Calmette-Guerin) and corynebaclerium parvum. Such adju
vants are also Well known in the art.
The use of monoclonal antibodies (MAbs) or derivatives

(e.g., a toxin and an inactivating agent). To link tWo different
proteins in a step-Wise manner, hetero bifunctional cross
linkers can be used Which eliminate the unWanted homopoly

thereof to C3a, C3aR, C5a and/or C5aR is preferred. MAbs
are recognized to have certain advantages, e. g., reproducibil

mer formation. An exemplary hetero bifunctional cross
linker contains tWo reactive groups: one reacting With

ity and large-scale production, that makes them suitable for
clinical treatment. The invention thus preferably provides
monoclonal antibodies of the murine, human, monkey, rat,

primary amine group (e.g., N-hydroxy succinimide) and the

hamster, rabbit and even frog or chicken origin. Murine,
human or humanized monoclonal antibodies Will generally

group, the cross-linker may react With the lysine residue(s) of
one protein (e.g., the selected antibody or fragment) and
through the thiol reactive group, the cross-linker, already tied
up to the ?rst protein, reacts With the cysteine residue (free

other reacting With a thiol group (e.g., pyridyl disul?de, male

imides, halogens, etc.). Through the primary amine reactive

be preferred. Preferably the anti-C3a antibody, anti-C3aR
antibody, anti-C5a antibody, and anti-C5aR antibody are neu
tralizing humanized rat or mouse lgG2a against human C3a,

sulfhydryl group) of the other protein (e. g., dgA).

C3aR, C5a and C5a, respectively.

The spacer arm betWeen these tWo reactive, groups of any

cross-linkers may have various lengths and chemical compo
sitions. A longer spacer arm alloWs a better ?exibility of the

Monoclonal antibodies to C3a, C3aR, C5a and C5aR can

be prepared using a Wide variety of techniques knoWn in the
art including the use of hybridoma, recombinant, and phage

conjugate components While some particular components in
the bridge (e. g., benzene group) may lend extra stability to the

display technologies, or a combination thereof. For example,

monoclonal antibodies can be produced using hybridoma
techniques including those knoWn in the art and taught, for
example, in HarloW et al., Antibodies: A Laboratory Manual,

reactive group or an increased resistance of the chemical link
20

to the action of various aspects (e.g., disul?de bond resistant

to reducing agents).

(Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Ham

Non-limiting examples of toxic agents to bind to anti-C3a,

merling, et al., in: Monoclonal Antibodies and T-Cell Hybri
domas 563-681 (Elsevier, N.Y., 1981). An exemplary anti

anti-C3aR, anti-C5a, or anti-C5aR antibodies include any

body to C5a is described in US. Pat. No. 5,177,190.

25

The ophthalmic compositions of this invention may further

attached to an inactivating agent include ot-emitters such as,
for example, 21 lAstatine, 212Bismuth and 213 Bismuth, as Well

comprise one or more pharmaceutical agent operatively
attached to the inactivating agent. In the context of the present

invention the selected pharmaceutical agent is thus targeted to
the RPE/choroid area of the eye by the inactivating agent,
alloWing selective inhibition of C3a, C3aR, C5a and/ or C5aR
activity and/ or treatment of an eye. The pharmaceutical agent
may comprise therapeutic agents such as any compound,
drug, molecule or protein having a desired therapeutic effect,
including, for example, the breakdoWn or clearance of
drusen, inhibition of CNV, inhibition of C3a, C3aR, C5a or
C5aR activity and/or the inhibition of VEGF expression.
Such other therapeutic agents may include anti-allergics,

as [3-emitters such as, for example, 131Iodine, 9OYttrium,
177Lutetium, 15 3 Samarium and 109 Palladium. Particularly
30

preferred radioisotopes are 211Astatine and 131Iodine. This
list is, of course, merely exemplary in that the technology for

attaching pharmaceutical agents to antibodies for speci?c
delivery to tissues is Well established.

The ophthalmic compositions of the present invention may
35

still further comprise one or more anti-in?ammatory agent

operatively attached to an inactivating agent. The ophthalmic
compositions of the present invention may contain one or

more inactivating agent that binds selectively to C3a, C3aR,

anti-angiogenics, anti-biotics, anti-cancer agents, anti-infec

tives, anti-in?ammatory agents, dry eye solutions, steroids,

chemical agents having localized cytotoxic effects and radio
isotopes. Exemplary radioisotopes that can be operatively

C5a and/or C5aR With one or a combination of a steroid drug,
40

such as triamcinolone, ?uocinolone, anacortave acetate, dex

and the like. This list is, of course, merely exemplary in that

amethasone and combinations thereof; or a non-steroidal

the technology for attaching pharmaceutical agents to antago

anti-in?ammatory drug, such as celecoxib, ?urbiprofen, and

nists for speci?c delivery to tissues is Well established.
A toxin bound anti-C3a, anti-C3aR, anti-C5a, or anti
C5aR antibody of the present invention comprises immuno
toxins. The preparation of immunotoxins is, in general, Well
knoWn in the art (see, e.g., US. Pat. No. 4,340,535, and EP

aspirin, for example.
45

pharmaceutical carriers can be sterile liquids, such as Water

and oils, including those of petroleum, animal, vegetable or
synthetic origin, such as peanut oil, soybean oil, mineral oil,

4416), hoWever, certain advantages may be achieved through
the application of certain preferred technology, both in the
preparation of the immunotoxins and in their puri?cation for
subsequent clinical administration. For example, While lgG
based immunotoxins Will typically exhibit better binding

The ophthalmic compositions of this invention may still
further comprise a pharmaceutically acceptable carrier. Such

50

and the like. Saline solutions and aqueous dextrose, polyeth
ylene glycol (PEG) and glycerol solutions can also be
employed as liquid carriers, particularly for injectable solu

tions. Suitable pharmaceutical excipients include starch, glu

capability and sloWer blood clearance than their Fab‘ coun

cose, lactose, sucrose, gelatin, malt, rice, sodium stearate,

terparts, Fab‘ fragment-based immunotoxins Will generally

glycerol monostearate, glycerol, propylene, glycol, Water,

exhibit better tissue penetrating capability as compared to
lgG based immunotoxins.

55

ering agents. The C3a and C5a inactivating agents, and any

Additionally, While numerous types of disul?de-bond con
taining linkers are knoWn Which can successfully be

employed to conjugate the toxin moiety With the antibody
inactivating agent, certain linkers Will generally be preferred

60

over other linkers, based on differing pharmacologic charac
teristics and capabilities. For example, linkers that contain a
disul?de bond that is sterically “hindered” are to be preferred,

due to their greater stability in vivo, thus preventing release of
the toxin moiety prior to binding at the site of action.
Cross-linking reagents are used to form molecular bridges
that tie together functional groups of tWo different proteins

and the like. The composition, if desired, can also contain
minor amounts of Wetting or emulsifying agents, or pH buff
combinations thereof or other active agents of the composi
tion may be encased in polymers or ?brin glues to provide
controlled release of the active agents. These compositions
can take the form of solutions, suspensions, emulsion, tablets,

pills, capsules, poWders, sustained-release formulations and
65

the like. Examples of suitable pharmaceutical carriers are
described in “Remington’s Pharmaceutical Sciences” by E.
W. Martin. Such compositions Will contain a therapeutically
effective amount of one or more of the inactivating agent,

preferably in puri?ed form, together With a suitable amount of

US 7,816,497 B2
11

12

carrier so as to provide the form for proper administration to

example, and not by Way of limitation, local infusion during
surgery, transscleral delivery, intravitreous injection, intrac

the patient. The formulation should suit the mode of admin
istration.

ameral injection, subretinal injection, topical application,

Ophthalmic pharmaceutical products are typically pack

e.g., in conjunction With a Wound dressing after surgery or via

drops or application of a gel or other topical solution, by

aged in multidose form. Preservatives are thus included to
prevent microbial contamination during use. Suitable preser

injection, or by means of an implant, said implant being of a
porous, non-porous, or gelatinous material, including mem
branes, such as sialastic membranes, or ?bers. Preferably,
When administering a protein, including an antibody or func
tional fragment thereof, of the invention, care must be taken to
use materials to Which the protein does not absorb.
In a preferred embodiment, the composition is adminis

vatives include: polyquaternium-l, benZalkonium chloride,

thimerosal, chlorobutanol, methyl paraben, propyl paraben,
phenylethyl alcohol, edetate disodium, sorbic acid, or other
agents knoWn to those skilled in the art. The use of

polyquatemium-l as the antimicrobial preservative is pre
ferred. Typically such preservatives are employed at a level of
from 0.001% to 1.0% by Weight.

tered by topical application to the eye. The ophthalmic com
positions are typically administered to the affected eye by

The solubility of the components of the present composi
tions may be enhanced by a surfactant or other appropriate

applying one to four drops of a sterile solution or suspension,

co-solvent in the composition. Such co-solvents include

or a comparable amount of an ointment, gel or other solid or

polysorbate 20, 60, and 80, polyoxyethylene/polyoxypropy

semisolid composition, to the surface of the affected eye one

lene surfactants (e.g., Pluronic F-68, F-84 and P-103), cyclo

to four times per day. HoWever, the compositions may also be

dextrin, or other agents knoWn to those skilled in the art.
Typically such co-solvents are employed at a level of from

0.01% to 2% by Weight.
The use of viscosity enhancing agents to provide the topi
cal compositions of the invention With viscosities greater than
the viscosity of simple aqueous solutions may be desirable to
increase ocular absorption of the active compounds by the

formulated as irrigating solutions that are applied to the
20

Topical compositions Will typically have a pH in the range

25

target tissues or increase the retention time in the eye. Such

viscosity building agents include, for example, polyvinyl
alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy
propyl methylcellulose, hydroxyethyl cellulose, carboxym
ethyl cellulose, hydroxy propyl cellulose or other agents

affected eye during surgical procedures.
of 4.5 to 8.0. The ophthalmic compositions must also be
formulated to have osmotic values that are compatible With
the aqueous humor of the eye and ophthalmic tissues. Such
osmotic values Will generally be in the range of from about
200 to about 400 milliosmoles per kilogram of Water

(“mOsm/kg”), but Will preferably be about 300 mOsm/kg.
In another preferred embodiment, the composition is for
mulated in accordance With routine procedures as a pharma
30

ceutical composition adapted for injection intravenously,

knoW to those skilled in the art. Such agents are typically

introperitoneally, or intravitreously. In a preferred embodi

employed at a level of from 0.01% to 2% by Weight.
The C3a, C3aR, C5a and/or C5aR inactivating agent-con

ment, the composition is administered by intravenous injec

taining compositions of the invention can be formulated as
neutral or salt forms. Pharmaceutically acceptable salts
include those formed With anions such as those derived from

tion. A high dose intravenous immunoglobulin (IVIG), as
35

function. Basta M. et al. F(ab)'2-mediated neutralization of
C3a and C5a anaphylatoxins: a novel effector function of

hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc.,
and those formed With cations such as those derived from

sodium, potassium, ammonium, calcium, ferric hydroxides,
isopropylamine, triethylamine, 2-ethylamino ethanol, histi

40

dine, procaine, etc.

45

ampoule or sachette indicating the quantity of active agent.
Where the composition is to be administered by infusion, it
50

55
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Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201
(1987); BuchWald et al., Surgery 88:507 (1980); Saudek et
al., N. Engl. J. Med. 321:574 (1989)). In another embodi
ment, polymeric materials can be used (see Medical Appli
cations of Controlled Release, Langer and Wise (eds.), CRC
Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailabil
ity, Drug Product Design and Performance, Smolen and Ball

65

romol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also

ing to the eye of a subject a therapeutically effective amount

of the compositions described herein. Preferably, administra
ment there is a method of using the compositions described
herein to

The compositions may be administered together With other
biologically active agents. Administration of the composi
tions of the invention may be systemic or local. Local admin
istration to the affected eye(s) may be achieved by, for

injection or saline can be provided so that the ingredients may
be mixed prior to administration.
A controlled release system may also be used to effect local
administration. In one embodiment, a pump may be used (see

for treating and/or preventing CNV comprising administer
tion of such one or more antagonist or antibody to C3a, C3aR,
C5a or C5aR reduces VEGF expression. In another embodi

can be dispensed With an infusion bottle containing sterile

pharmaceutical grade Water or saline. Where the composition
is administered by injection, an ampoule of sterile Water for

in vitro or animal model test systems.

Methods of the Invention
In another aspect of this invention there is provided meth
ods of treating AMD. In one embodiment there are methods

pain at the site of the injection. Generally, the ingredients are
supplied either separately or mixed together in unit dosage
form, for example, as a dry lyophiliZed poWder or Water free
concentrate in a hermetically sealed container such as an

the formulation Will also depend on the route of administra
tion, and the seriousness of the neovascular disease or disor

der, and should be decided according to the judgment of the
practitioner and each patient’ s circumstances. Effective doses
may be extrapolated from dose-response curves derived from

immunoglobulins. Nature Medicine 2003; 91431-8. In
another preferred embodiment the composition is adapted for
intravitreous injection to the eye. Typically, compositions for
injection are solutions in sterile isotonic aqueous buffer.
Where necessary, the composition may also include a solu
biliZing agent and a local anesthetic such as lignocaine to ease

The amount of the active agents of the compositions of the
invention Which Will be effective in the treatment, inhibition
and/or prevention of neovasculariZation of the eye can be

determined by standard clinical techniques. In addition, in
vitro assays may optionally be employed to help identify
optimal dosage ranges. The precise dose to be employed in

Well as F(ab)2-IVIG and even irrelevant human monoclonal
antibodies all can bind C3a and C5a and interfere With their

(eds.), Wiley, NeW York (1984); Ranger and Peppas, 1., Mac
Levy et al., Science 228:190 (1985); During et al., Ann.
Neurol. 25:351 (1989); HoWard et al., J. Neurosurg. 71:105

US 7,816,497 B2
13

14

(1989)). In yet another embodiment, a controlled release sys
tem can be placed in proximity of the eye.

to alloW the formation of immune complexes (primary
immune complexes) is generally a matter of simply adding an

Various other delivery systems are known and can be used
to administer a composition of the invention, e.g., encapsu

ture for a period of time lone enough for the antibodies to

antibody composition to the sample and incubating the mix

lation in vesicles, liposomes, microparticles, microcapsules,
receptor-mediated endocytosis (See, e. g., Wu and Wu, J. Biol.

form immune complexes With, i.e., to bind to, any C3a, C3aR,
C5a and/or C5aR present. After this time, the sample-anti
body composition, such as a tissue section, ELISA plate, dot

recombinant cells capable of expressing the compound,
Chem. 262:4429-4432 (1987)), construction of a nucleic acid

blot or Western blot, Will generally be Washed to remove any

as part of a retroviral or other vector, etc. In one embodiment,

non-speci?cally bound antibody species, alloWing only those

the composition of the invention can be delivered in a vesicle,

antibodies speci?cally bound Within the primary immune
complexes to be detected.
Immunoassays of the present invention Which utilize the
monoclonal antibodies are competitive and non-competitive

in particular a liposome (See Langer, Science 249: 1 527-1 533
(1990); Treat et al., in Liposomes in the Therapy of Infectious

Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss,
NeW York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp.
317-327; see generally ibid.).
Diagnostics of the Invention
The present invention further provides in vitro and in vivo
diagnostic methods, assays and kits. Such methods are appli
cable for use in generating diagnostic, prognostic or imaging
information for any neovascular disease, as exempli?ed by

immunoassays in either a direct or indirect format, forWard,
reverse, or simultaneous modes, including, the radioimmu

noassay (RIA) and the sandWich (immunometric) assay and
immunohistochemical assays on physiological samples.
Those of skill in the art Will knoW, or can readily discern, other

immunoassay formats Without undue experimentation.
20

age-related macular degeneration.
In one embodiments, the present invention concerns

immunodetection methods for binding, purifying, removing,
quantifying or otherWise generally detecting C3a, C3aR, C5a

upon the detection of a label or marker, such as any radioac

and/or C5aR and for diagnosing neovascular disease, like
AMD, of the eye. The antibodies to C3a, C3aR, C5a and
C5aR of the present invention may be employed to detect
C3a, C3aR, C5a and/ or C5aR, respectively, in vivo (see
beloW), in isolated issue samples, biopsies or sWabs and/or in

25

homogenized tissue samples. Such immunodetection meth
ods have evident diagnostic utility, but also have applications
to non-clinical samples, such as in the titering of antigen
samples, and the like.

30

The steps of various useful immunodetection methods
have been described in the scienti?c literature, such as, e.g.,

of enzymes that generate a colored product upon contact With

a chromogenic substrate are generally preferred. Secondary

35

40

matrix, and the sample suspected of containing C3a and/or
45

formation of secondary immune complexes. The secondary
immune complexes are then generally Washed to remove any
50

non-speci?cally bound labeled secondary antibodies or

ligands, and the remaining label in the secondary immune
complexes is then detected.

plexes formed under the speci?c conditions.
The biological sample analyzed may be any sample that is
suspected of containing C3a, C3aR, C5a and/or C5aR, gen

Further methods include the detection of primary immune

complexes by a tWo step approach. A second binding ligand,
55

tion or specimen, a biopsy, a sWab or smear test sample, a

such as an antibody, that has binding a?inity for the ?rst
antibody is used to form secondary immune complexes, as
described above. After Washing, the secondary immune com
plexes are contacted With a third binding ligand or antibody

that has binding af?nity for the second antibody, again under
60

commonly used in histological diagnosis. Preferably, the
sample is a sample from plasma, serum, or the vitreous
humor, subretinal space, anterior changer, tear ?lm of the eye.

antibody, and may thus be termed a “secondary” antibody.
The primary immune complexes are contacted With the

labeled, secondary binding ligand, or antibody, under condi

With and then detect or quantify the amount of immune com

homogenized tissue extract or separated or puri?ed forms of
such. A sample can be a liquid such as ?uids of the eye such
as tears, urine, saliva, cerebrospinal ?uid, blood, serum or the
like; a solid or semi-solid such as vitreous humor, tissues,
feces, or the like; or, alternatively, a solid tissue such as those

mined.
In one embodiment the primary immune complexes are
detected by means of a second binding ligand that has binding
a?inity for the antibodies of the invention. In such cases, the
second binding ligand may be operatively attached to a
detectable label. The second binding ligand is itself often an

tions effective and for a period of time su?icient to alloW the

sample suspected of containing C3a, C3aR, C5a and/or C5aR

erally from an animal or patient suspected of having an
neovascular disease. The samples may be a ?uid, tissue sec

used, as is knoWn in the art.
The anti-C3a, anti-C3aR, anti-C5a, and/ or anti-C5aR anti
bodies employed in the detection may themselves be opera
tively attached to a detectable label, Wherein one Would then

simply detect this label, thereby alloWing the amount of the
primary immune complexes in the composition to be deter

linked to a solid support, such as in the form of a column

and contact the sample With an antibody in accordance here

binding ligand, such as a second antibody or a biotin/avidin or

biotin/streptavidin ligand binding arrangement, may also be

antibodies under conditions effective to alloW the formation

C5a Will be applied to the immobilized antibody.
More preferably, the immunobinding methods include
methods for detecting or quantifying the amount of C3a,
C3aR, C5a and/ or C5aR in a sample, Which methods require
the detection or quanti?cation of any immune complexes
formed during the binding process. Here, one Would obtain a

tive, ?uorescent, biological or enzymatic tags or labels knoWn
in the art. Exemplary US. patents concerning the use of such
labels include US. Pat. Nos. 3,817,837; 3,850,752; 3,939,

350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Theuse

Nakamura et al. (1987). In general, the immunobinding meth
ods include obtaining a sample suspected of containing C3a
and/or C5a and contacting the sample With C3a and/or C5a

of immunocomplexes. In such methods, the antibody may be

The detection of immunocomplex formation is also Well
knoWn in the art and may be achieved through the application
of numerous approaches. These methods are generally based

65

conditions effective and for a period of time su?icient to alloW
the formation of immune complexes (tertiary immune com
plexes). The third ligand or antibody is operatively attached to
a detectable label, alloWing detection of the tertiary immune

complexes thus formed. This system may provide for signal
ampli?cation if desired.

Introducing the chosen biological sample to the antibody

In the clinical diagnosis or monitoring of patients With an

under conditions effective and for a period of time su?icient

neovascular disease, the detection of C3a, C3aR, C5a, and/or

US 7,816,497 B2
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C5aR, or an increase in the levels of C3a, C3aR, C5a and/or

photons in the 140-250 keV range, Which may be readily

C5aR, in comparison to the levels in a corresponding biologi
cal sample from a normal subject is indicative of a patient

detected by conventional gamma cameras.

With an neovascular disease.
HoWever, as is knoWn to those of skill in the art, such a

markers or labels are required that can be detected using

In antibody conjugates for in vivo diagnostic protocols
non-invasive methods. Many appropriate detectable markers

clinical diagnosis Would not likely be made on the basis of

or labels are knoWn in the art, as are methods for their attach

this method in isolation. Those of skill in the art are very

ment to antibodies and binding ligands (see, e.g., U.S. Pat.
Nos. 5,021,236 and 4,472,509). Examples of such labels
include those that are, absorbant-based, chemiluminescent,

familiar With differentiating betWeen signi?cant expression
of a biomarker, Which represents a positive identi?cation, and
loW level or background expression of a biomarker. Indeed,

?uorescent, nuclear magnetic spin-resonance, paramagnetic,

background expression levels are often used to form a “cut

radioactive, x-ray detectable, or a combination of the forego
ing. Certain attachment methods involve the use of a metal

off” above Which increased staining Will be scored as signi?
cant or positive.

chelate complex employing, for example, an organic chelat

The in vivo diagnostic or imaging methods generally com
prise administering or introducing to a patient a diagnosti
cally effective amount of a C3a, C3aR, C5a and/or C5aR
antibody that is operatively attached to a marker or label that

ing agent such a DTPA attached to the antibody (U .8. Pat. No.
4,472,509). Monoclonal antibodies may also be reacted With
an enZyme in the presence of a coupling agent such as glut

araldehyde or periodate. Conjugates With ?uorescein markers
are prepared in the presence of these coupling agents or by

is detectable by non-invasive methods. The antibody-marker
conjugate is alloWed su?icient time to localiZe and bind to

C3a, C3aR, C5a and/or C5aR Within the eye. The patient is

20

then exposed to a detection device to identify the detectable

marker, thus forming an image of the location of C3a, C3aR,
C5a and/ or C5aR in the eye of a patient. The presence of C3a,
C3aR, C5a, C5aR or a combination thereof is detected by
determining Whether an antibody-marker binds to a compo
nent of the eye. Detection of or an increased level in C3a,
C3aR, C5a, C5aR or a combination thereof in comparison to
a normal individual Without neovascular disease is indicative
of a predisposition for and/or on set of neovascular disease. In
a preferred embodiment of the invention there is provided an

(II), iron (III), iron (II), cobalt (II), nickel (II), copper (II),

neodymium (III), samarium (III), ytterbium (III), gadolinium
25

Ions useful in other contexts, such as X-ray imaging,
include but are not limited to lanthanum (III), gold (III), lead
30

in vivo assay for detecting the presence of C3a, C3aR, C5a, or

?uorescein are often operatively attached via an isothiocyan

In the case of radioactive isotopes for diagnostic applica
35
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rheniuml 88,

rubidium97,
and

yttriumgo. 125 I is often being preferred for use in certain
embodiments, and technicium99’" and indiunl l l are also often

detection.
45

In the case of nuclear magnetic spin-resonance isotope,
suitable examples include cobalt (II), copper (II), chromium

(III), dysprosium (III), erbium (III), gadolinium (III), hol
mium (III), iron (II), iron (III), manganese (II), neodymium
(III), nickel (II), samarium (III), terbium (III), vanadium (II)
50

or ytterbium (III); or rhodamine or ?uorescein.
Radioactively labeled C3a and/ or C5a antibodies for use in

the present invention may be produced according to Well
knoWn methods in the art. For instance, intermediary func
55

tional groups that are often used to bind radioisotopic metallic
ions to antibodies are diethylenetriaminepentaacetic acid

(DTPA) and ethylene diaminetetracetic acid (EDTA).

For in vivo diagnostic imaging, the type of detection instru
ment available is a major factor in selecting an appropriate
label or marker, like a radioisotope. The radioisotope chosen
must have a type of decay Which is detectable for the given

rheniuml 86,

rubidiuml O3 , 75 selenium, 3 5 sulphur, technetium99’"

preferred due to their loW energy and suitability for long range

example, depending on Whethermultiple injections are given,
on the tissue being assayed, and other factors knoWn to those
of skill in the art.

36chlorine, 57cobalt, 58cobalt, copper67, 152Eu, gallium67,
gallium68, 3hydrogen, iodine123, iodinel25, iodinel3l,
indiuml 13, indiuml 1 3 , 5 9iron, mercuryl97, mercury2O3,

bearing cells, is detectable compared to the background. Fur

less than for therapy, but are also dependent upon the age,
gender, Weight and extent of disease of a patient. One time
doses should be su?icient. The dosage of the compound can
vary from about 0.01 mg/kg to about 500 mg/kg, preferably
about 0.1 mg/kg to about 200 mg/kg, most preferably about
0.1 mg/kg to about 10 mg/kg. Such dosages may vary, for

tions, suitable examples include l4carbon, 51chromium,

32pho sphorus,

ther, it is desirable that the detectably labeled antibody or

compound be rapidly cleared from the circulatory system in
order to give the best target-to-background signal ratio.
Dosages for in vivo imaging embodiments are generally

(II), and especially bismuth (III). Fluorescent labels include
rhodamine, ?uorescein and renographin. Rhodamine and
ate intermediate.

imaging methods and combined angiogenic diagnostic and
The anit-C3a, anti-C3aR, anti-C5a, and/ or anti-C5aR anti
bodies or binding compounds or ligands for the in vivo detec
tion of C3a, C3aR, C5a and/or C5aR, respectively, are given
in a dose Which is diagnostically effective. The concentration
of detectably labeled antibody or compound Which is admin
istered should be suf?cient such that the binding to C3a,
C3aR, C5a, or C5aR and/or C3a-, C3aR-, C5a- and/or C5aR

(III), vanadium (II), terbium (III), dysprosium (III), holmium
(III) and erbium (III), With gadolinium being particularly

preferred.

C5aR as a predisposition for or early detection of AMD.
These aspects of the invention are also preferred for use in eye
treatment methods.

reaction With an isothiocyanate.
An example of detectable labels are the paramagnetic ions.
In this case, suitable ions include chromium (III), manganese

60

Monoclonal antibodies can also be iodinated by contact
With sodium or potassium iodide and a chemical oxidiZing
agent such as sodium hypochlorite, or an enZymatic oxidiZing
agent, such as lactoperoxidase. Antibodies according to the

type of instrument. Still another important factor in selecting

invention may be labeled With technetium-99em by ligand

a radioisotope for in vivo diagnosis is that the half-life of the
radioisotope be long enough such that it is still detectable at

exchange process, for example, by reducing pertechnate With

the time of maximum uptake by the target, but short enough

Sephadex column and applying the antibody to this column;
or by direct labeling techniques, e.g., by incubating pertech

such that deleterious radiation With respect to the host is

stannous solution, chelating the reduced technetium onto a
65

acceptable. Ideally, a radioisotope used for in vivo imaging

nate, a reducing agent such as SNCl2, a buffer solution such as

Will lack a particle emission but produce a large number of

sodium-potassium phthalate solution, and the antibody.

US 7,816,497 B2
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Any of the foregoing type of detectably labeled anti-C3a,

various eye ?uids, it Would be possible to determine Whether

a particular therapeutic regimen aimed at ameliorating the

anti-C3aR, anti-C5a and/or anti-C5aR antibodies may be
used in the imaging or combined imaging and diagnostic
aspects of the present invention. They are equally suitable for

AMD is effective.
EXAMPLES

use in in vitro diagnostics.

In still another aspect, the present invention provides diag
nostic kits, including both immunodetection and imaging

The folloWing examples are presented for the illustrative

kits, for use With the immunodetection and imaging methods

described above. Accordingly, the anti-C3a, anti-C3aR, anti

purposes and it is to be understood that the present invention
is not limited to those precise embodiments. It should be

C5a and/or anti-C5aR antibodies are provided in the kit,
generally comprised Within a suitable container.

appreciated by those of skill in the art that the techniques
disclosed in the examples Which folloW represent techniques

For immunodetection, the antibodies may be bound to a
solid support, such as a Well of a microtitre plate, although
antibody solutions or poWders for reconstitution are pre

to function Well in the practice of the invention, and thus can
be considered to constitute preferred modes for its practice.

HoWever, those of skill in the art should, in light of the present
disclosure, appreciate that many changes can be made in the

ferred. The immunodetection kits preferably comprise at least

speci?c embodiments Which are disclosed and still obtain a

a ?rst immunodetection reagent. The immunodetection
reagents of the kit may take any one of a variety of forms,
including those detectable labels that are operatively attached
to the given antibody. Detectable labels that are associated
With or attached to a secondary binding ligand are also con

like or similar result Without departing from the spirit and
scope of the invention.

Example 1

20

templated. Exemplary secondary ligands are those secondary

Animals

antibodies that have binding a?inity for the ?rst antibody.
Further suitable immunodetection reagents for use in the
present kits include the tWo-component reagent that com

prises a secondary antibody that has binding a?inity for the
?rst antibody, along With a third antibody that has binding
a?inity for the second antibody, the third antibody being

Male C3aR_/_ and C5aR_/_ mice, backcrossed 6 times to
25

(Jackson Labs) betWeen 6 and 8 Weeks of age Were used to
minimiZe variability. For all procedures, anesthesia Was

operatively attached to a detectable label. As noted above, a
number of exemplary labels are knoWn in the art and all such

labels may be employed in connection With the present inven
tion. These kits may contain antibody-label conjugates either
in fully conjugated form, in the form of intermediates, or as
separate moieties to be conjugated by the user of the kit.
The imaging kits Will preferably comprise an antibody to

30

C3a, C3aR, C5a and/ or C5aR that is already attached to an in
vivo detectable label. HoWever, the label and attachment

35

C5aR, Whether labeled or unlabeled, as may be used to pre

Zine (Phoenix Scienti?c), and pupils Were dilated With topical
1% tropicamide (Alcon).

Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 um)
40

Sakurai, E., Taguchi, H., Anand, A., Ambati, B. K., Gragou

lyophiliZed form.
45

sured by scanning laser confocal microscope (TCS SP, Leica)
50

placed. The kits may also include other diagnostic reagents
for use in the diagnosis of any one or more neovascular
55

Example 3

Complement Inhibition

The C3a receptor antagonist (C3aRA) N2-[(2,2-diphe
60

ligands in vitro and in vivo to monitor the course of therapy

nylethoxy)acetyl]-arginine (Ames, R. S., Lee, D., Foley, J. J .,
JureWicZ, A. J ., Tometta, M. A., Bautsch, W., Settmacher, B.,

Klos, A., Erhard, K. E, Cousins, R. D., SulpiZio, A. C.,
Hieble, J. P., McCaffer‘ty, G., Ward, K. W., Adams, J. L.,
Bondinell, W. E., Underwood, D. C., Osborn, R. R., Badger,

for neovascular disease, like AMD. Thus, for example, by
measuring the increase or decrease in the biological mol
ecules associated With such a diseases or changes in the

as previously reported (Id.) With 0.5% FITC-Grz?bnia sim
plicifolia Isolectin B4 (Vector Laboratories) or 0.5% FITC
rat antibody against mouse CD3 1 (BD Phar'mingen).Volumes
obtained by lectin and CD31 staining Were highly correlated

(r2:0.95).

monitoring method utiliZing the antibodies and compounds/

concentration of C3a, C3aR, C5a and/or C5aR, or C3a-,
C3aR-, C5a- and/or C5a-bearing cells present in the eye or in

das, E. S., Miller, J. W., Adamis, A. P. & Ambati, J. (2003)
Invest Ophthalmol l/zs Sci 44, 2743-9; and Sakurai, E.,Anand,
A., Ambati, B. K., van Rooijen, N. &Ambati, J. (2003) Invest
Ophthalmol Vis Sci 44, 3578-85. CNV volumes Were mea

placed, and preferably, suitably aliquoted. Where a second or
third binding ligand or additional component is provided, the

diseases.
The kits of the present invention Will also typically include
a means for containing the antibody, and any other reagent
containers in close con?nement for commercial sale. Such
containers may include injection or bloW-molded plastic con
tainers into Which the desired vials are retained.
In another aspect of the invention there is provided a cell

(OcuLight GL, Iridex) Was performed (volume studies:
3/eye; protein analyses/?ow cytometry: 12/ eye) on both eyes
of each animal to induce CNV as previously described in

of the kits may be packaged either in aqueous media or in

kit Will also generally contain a second, third or other addi
tional container into Which this ligand or component may be

Example 2
CNV

pare a standard curve for a detection assay. The components

The container means of the kits Will generally include at
least one vial, test tube, ?ask, bottle, syringe or other con
tainer means, into Which the antibody or antigen may be

achieved by intramuscular injection of 50 mg/kg ketamine

hydrochloride (Ft. Dodge Animal Health) and 10 mg/kg xyla

means could be separately supplied.
Either kit may further comprise control agents, such as

suitably aliquoted compositions of C3a, C3aR, C5a and/or

C57BL/6J, generated as described previously (Hopken, U. E.,
et al. (1996) Nature 383, 86-9; and Humbles, A. A., et al.,
(2000) Nature 406, 998-1001), andWild-type C57BL/6J mice

65

A. M. & Sarau, H. M. (2001).]Immun0l 166, 6341-6348) and

C5a receptor antagonist (C5aRA) AcF[OPdChaWR] (Finch,
A. M., Wong,A. K., PacZkoWski, N. J., Wadi, S. K., Craik, D.
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J., Fairlie, D. P. & Taylor, S. M. (1999) JMed Chem 42,
1965-74), Were synthesized as previously described (Reca,

Example 7

R., Mastellos, D., Majka, M., Marquez, L., Ratajczak, J.,
Franchini, S., Glodek, A., Honczarenko, M., Spruce, L. A.,

Western Blotting

JanoWska-Wieczorek, A., Lambris, J. D. & Ratajczak, M. Z.

Equal amounts of total protein from RPE/choroid Were

(2003) Blood 101, 3784-93; Mastellos, D., Papadimitriou, J.

resolved in SDS 4-20% polyacrylamide gradient gel and

C., Franchini, S., Tsonis, P. A. & Lambris, J. D. (2001) J
Immunol 166, 2479-86). A nonsense peptide (IAVVQD
WGHHRAT), synthesized as described previously (Sahu, A.,
Soulika, A. M., Morikis, D., Spruce, L., Moore, W. T. &

transferred to nitrocellulose membranes for Western blotting
With chicken antibodies to mouse C3 or mouse C5 (1: 100; gift

of S. R. Barnum, University of Alabama, Birmingham).
Equal loading Was assessed by blotting With rabbit antibody
to human GAPDH (1 :2,000; Abcam).

Lambris, J. D. (2000) Jlmmunol 165, 2491-9), Was used as

control. Rat IgG2a antibody against mouse C3a (clone 3/11;

Hycult Biotechnology), Which inhibits C3a activity (unpub
lished data, J.D.L.), and rabbit polyclonal IgG antibody

Example 8

against a synthetic peptide constructed from the carboxyl
terminal region of rat C5a (Huber-Lang, M. S., Sarma, J. V.,
McGuire, S. R., Lu, K. T., Guo, R. E, Padgaonkar, V. A.,
Younkin, E. M., Laudes, I. J ., Riedemann, N. C.,Younger, J.
G. & Ward, P. A. (2001) FASEB J 15, 568-70), Which also

FloW Cytometry

inhibits mouse C5a (unpublished data, J .V.S.), and Were used
to block C3a and C5a. Rabbit IgG and rat IgG2a (Jackson

Single cell suspensions isolated from mouse RPE/choroids

via collagenase D treatment (20 U/mL; Roche Diagnostics)
Were incubated in Fc block (0.5 mg/mL; BD Pharmingen) for
20

Immunoresearch) Were used as controls. These reagents Were

eBioscience), and subjected to FACS analysis (FACScalibur,

injected into the vitreous humor of Wild-type mice using a
33-gauge Hamilton syringe either immediately after or three

days after laser injury.

15 min on ice, stained With Cy5 -rat antibody to mouse F4/ 80

(1 :30; Serotec), FITC-hamster antibody to mouse CD1 1c
(1:100; Serotec), or PE-rat antibody to mouse Gr-1 (1:200;

BD Biosciences). Macrophages and neutrophils Were de?ned
25

as F4/80+CD1 1c- and Gr-1+F4/80-cells, respectively.

Example 9

Example 4

Immunohistochemistry

StatisticsiVolume of CNV
30

blocked With 5% donkey serum (Jackson lmmunoresearch)

Because the probability of each laser lesion developing
CNV is in?uenced by the group to Which it belongs, the

Were stained With chicken antibodies against mouse C3

mouse, the eye, and the laser spot, the mean lesion volumes

Frozen sections ?xed in Histochoice MB (Amresco) and

(1:750) or C5 (1 :5,000; both gifts ofS. R. Barnum, University
of Alabama, Birmingham). Bound antibody Was detected
With Cy3-donkey secondary (1:750; Jackson Immunore
search). Rabbit antibody against mouse RPE65 (1 :1,000; gift
of M. Redmond, National Eye Institute, Bethesda) in con

35

signi?cance Was determined at the 0.05 level. Post hoc com
parison of means Was constructed With a Bonferroni adjust

junction With Alexa 488-donkey secondary (1 :200; Molecu
lar Probes) Was used to localize RPE cells. Cell nuclei Were

Were compared using a linear mixed model With a split plot
repeated measures design, as previously described. Id. The
Whole plot factor Was the genetic group to Which the animal
belonged While the split plot factor Was the eye. Statistical

40

ment for multiple comparisons.

stained With 4',6'-diamino-phenylindole (DAPI; Molecular

Example 10

Probes).

Protein Levels and FloW Cytometry

Example 5
45

VEGF protein data are represented as the meanis .e.m. of at

Cell Culture

least 3 independent experiments and compared using a tWo
tailed Student’s t-test. The null hypothesis Was rejected at
P<0.05.

Human RPE cells (gift of David R. Hinton, University of
Southern California) Were cultured in Dulbecco’s modi?ed

essential medium (Invitrogen) containing 10% fetal bovine

50

serum, penicillin G (100 U/ml), streptomycin sulfate (0.1

Example 11

mg/ml) (all from Sigma-Aldrich) at 370 C. under 10% CO2

Diagnostic Assay

and 90% room air. Cells Were used for experiments upon
attaining 80% or 100% con?uence.
55

Example 6
VEGF ELISA
The RPE/ choroid complex Was dissected from the mouse

60

eye and sonicated in lysis buffer (20 mM imidazole HCl, 10
mM KCl, 1 mM MgCl2, 10 mM EGTA, 1% Triton X-100, 10
mM NaF, 1 mM Na molybdate, 1 mM EDTA With protease
inhibitor (Sigma-Aldrich)) on ice for 45 sec. VEGF protein
levels (pg/ml) in the RPE cell culture supernatant or the

RPE/choroid lysate Were determined by ELISA (R&D Sys
tems) and normalized to total protein (pg/ml) (Bio-Rad).

Anti-C3a, anti-C3aR, anti-C5a and/or anti C5aR antibod
ies are labeled With ?uorescein, indocyanine green, or conju
gates thereof. The labeled antiC3a and C5a antibodies or Fab
fragments thereof are injected into the vitreous humor of the

eye or intravenously and detected by ?uorescent imaging
using appropriate excitation and emission ?lters through a

dilated pupil.
What is claimed is:

1. A pharmaceutical composition for treating and/or pre
venting choroidal neovascularization (CNV) comprising, a
65

therapeutically effective amount of an antibody that binds

selectively to the receptor of C3a (C3aR), and prevents cho
roidal neovascularization and an ophthalmically acceptable
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pharmaceutical carrier, wherein the antibody comprises a
4. The composition of claim 3 Wherein the radioisotope is
pharmaceutical agent operatively attached thereto.
21 lAstatine or 131Iodine.
2. The composition according to claim 1 Wherein the phar5. The composition of claim 1 Wherein said composition is
maceutical agent is an anti-in?ammatory agent.
formulated for intravitreous injection.
3. The composition of claim 1 Wherein the pharmaceutical 5
agent is a radioisotope.
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